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There is no consensus about a case definition of benign prostatic hyperplasia (BPH). In the present study, BPH 
prevalence rates were determined using various case definitions based on a combination of clinical parameters 
used to describe the properties of BPH: symptoms of prostatism, prostate volume increase, and bladder outflow 
obstruction. The aim of this study-in a community-based population of 502 men (55-74 years of age) without 
prostate cancer-was to determine the relative impact on prevalence rates of the inclusion of these different 
parameters (and of different cutoff values for these parameters) in a case definition of BPH. There is agreement 
that age is the dominant determinant of BPH. However, of 28 different case definitions that were formulated, 
only eight gave a statistically significant increase in the prevalence of BPH with age. The highest overall 
prevalence of 19% (95% confidence interval [Cl], 1 S-23%) occurred using the definition that combines a 
prostate volume >30 cm3 and an International Prostate Symptom Score (IPSS) >7. The lowest prevalence rate 
of 4.3% (95% Cl, 2-6%) occurred using the definition that combines a prostate volume >30 cm3, an IPSS >7, 
a maximum flow rate <lo mL/s, and the presence of a postvoid residual urine volume ~50 mL. Thus, preva- 
lence rates depend very much on the parameters used in a case definition. Follow-up will establish which men 
will eventually request a workup and treatment for BPH and will help determine the best clinical definition of 
BPH. UROLOGY” 46: 34-40, 1995. 
T ransurethral resection of the prostate for benign prostatic hyperplasia (BPH) is one of most com- 
mon surgical 
1P 
rocedures performed in men >65 
years of age. ’ However, prostatectomy rates are 
poor indicators of the prevalence of the disease be- 
cause of biases related to thresholds of referral, avail- 
ability of health facilities, and differing decision algo- 
rithms among surgeons.’ The classic clinical picture 
of BPH has been described as a combination of three 
properties: an increased prostate volume, the pres- 
ence of symptoms of prostatism, and evidence of 
bladder outflow obstruction.3 However, there is no 
consensus about a clinical case definition of BPH, 
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primarily because there is neither agreement about 
the parameters that should be used to describe the 
properties of BPH, nor about the normal range of 
values for these parameters. There is also a lack of 
strong correlation between these parameters. It is, 
therefore, necessary to address the three properties of 
BPH separately before they are considered in relation 
to each other and before they can be used to estimate 
the prevalence of BPH in the community. 
The present study attempted to define the syn- 
drome of BPH in various ways based on relevant pa- 
rameters used in daily clinical practice: the validated 
International Prostate Symptom Score (IPSS),4 pros- 
tate volume, and parameters used to screen for blad- 
der oufflow obstruction, i.e., urinary flow rate and 
postvoid residual urine volume. No preselection was 
made on the basis of symptoms, prostate volume, or 
urinary flow rate. 
MATERIALS AND METHODOLOGY 
STUDY DESIGN 
The community-based data on BPH presented in 
this article were collected as part of a randomized 
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pilot study designed to evaluate the value of screen- 
ing for prostate cancer. The municipal authorities of 
the city of Rotterdam created a database containing 
the addresses of all men aged 55-74 years residing in 
four areas of the city. A total of 1186 men accepted 
the invitation to participate in the study and were 
stratified into four 5-year age groups between 55 and 
74 years. The response rates for the four age groups 
varied between 33% and 36.3%. This resulted in a 
community-based population with a slight over- 
representation of men aged 60-64 years and a slight 
under-representation of men aged 55-59 years 
(Table I). 
Serum prostate-specific antigen (PSA; Hybritech 
assay) was used as a prescreening tool. If the PSA 
value was >lO ng/mL, a workup was advised be- 
cause of the high probability of prostate cancer.5 Of 
30 men who were excluded from randomization in 
the study, 15 were ultimately diagnosed with pros- 
tate cancer. 
The remaining 1156 men were randomly assigned 
to a screening or a no screening group. The 554 men 
assigned to the screening group were further exam- 
ined by digital rectal examination (DRE) and trans- 
rectal ultrasound (TRUS) of the prostate. Prostate 
biopsies were taken if DRE or TRUS, or both, were 
abnormal. The 10 men in whom biopsies were posi- 
tive for prostate cancer, the 39 who had undergone a 
previous operation of the lower urinary tract, and the 
3 who refused the TRUS examination were excluded 
from the evaluation of the prevalence of BPH. Thus, a 
community-based population was established com- 
prising 502 men in whom prostate cancer had been 
excluded with reasonable certainty and who had not 
previously undergone a prostate operation. 
This study of the prevalence of BPH was one of 
several substudies planned from the screen versus no 
screen pilot study. The parameters studied included 
uroflowmetry and the determination of the postvoid 
residual urine volume by transabdominal ultra- 
sound, performed in 494 and 326 consecutive men, 
respectively. 
PROCEDURES 
Symptoms: The symptom questionnaire used is 
the validated American Urological Association 
(AUA) index,6 which has been adopted by the World 
Health Organization as the IPSS after addition of one 
disease-specific quality of life question (scale O-6).4 
Based on correlations between the symptom index 
and other scores, three subclasses of men were cre- 
ated according to total score results: those with 
minor (IPSS O-7), moderate (IPSS 8-19), and severe 
(IPSS 20-35) symptoms6 
An analysis of the symptom scores in this commu- 
TABLE I. Frequency distribution of men in four 
age groups between 5.5 and 74 years of age in the 
general community population and in the 
population of study participants 
Age Community Study 
(yr) Population (%) Participants (%) 
55-59 25.8 20.9 
60-64 27.9 32.0 
65-69 25.6 26.1 
70-74 20.7 21.0 
Total 100 100 
nity-based sample of men showed a weak correlation 
between age and total IPSS (I = 0.09; P = 0.04).7 
Overall, 70% of the men had no or minor symptoms, 
24Ob were moderately symptomatic, and 6% were 
severely symptomatic. There was only a small varia- 
tion among age groups in the percentage of men with 
severe symptoms (range, 5.3-6.5%). 
Prostate Volume: TRUS was performed with a 7 
MHz multiplane sector scanning probe (Btuel & 
Kjaer). The planimetric technique of volume mea- 
surement was used.* The reliability of this method 
has been shown in a previous study.g Because the 
specific gravity of prostatic tissue is approximately 
1 ,l” the prostate volume in cubic centimeters as de- 
termined by the ultrasound method was directly 
compared with prostate weight in grams when com- 
parisons were made with other studies reporting 
prostate weights. An analysis of prostate volume in 
this community-based sample of men showed a weak 
correlation between total prostate volume and age 
(r = 0.26; P <O.OOl).” Almost all men (95%) aged 
55-74 years have a prostate volume of >20 cm’. 
There is a statistically significant trend (P <O.OOl) 
for an increase in the percentage of men with a vol- 
ume of >30 cm3 per 5-year age interval, as well as in 
the percentage of men with volumes >40 and >50 
cm3. 
Urodynumic Parameters : Uroflowmetry (nVs> 
was done using a flowmeter (Dantec Urodyn lO@J>; 
the maximum flow rate (Q-1 and the accompany- 
ing voided volume were recorded. The postvoid re- 
sidual urine volume (in milliliters) was measured by 
transabdominal ultrasound using an Aloka machine 
with a 3.5 MHz hand-held probe. Volume was calcu- 
lated using the formula’2: 
7r/6 x (width) X (height) X (depth) 
An analysis of the urodynamic parameters showed 
that of 494 consecutive men who were asked to void 
in the flowmeter, 62 (13%) were unable to do so at 
that particular moment.’ The initial bladder volume 
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was 2 100 mL in 83% of those men who voided. In 
the prevalence estimations of clinical BPH, those 
men who could not void were categorized as having a 
flow rate below the chosen cutoff value (either 10 or 
15 mUs>. On average, 76% of the men had a maxi- 
mum flow rate of Cl5 mUs and 43% had a maxi- 
mum flow rate of <lo mIJs. The correlation be- 
tween maximum flow rate and age was not 
significant (r = -0.08; P = 0.08). 
No flow rates were discarded because of low vol- 
ume. Thus, the flow rate data indicate the results 
obtained in a setting where men can be seen only 
once, as would be the case in population studies of 
the prevalence of BPH and related symptoms. The 
flow rate values would probably have been some- 
what higher if repeated measurements were made in 
selected patients. Overall, 17% of the men in whom 
uroflowmetry was performed had a residual urine 
volume >50 mL. There was a statistically significant 
trend (P = 0.004) for an increase in this percentage 
with age, from 12% for men 55-64 years, versus 18% 
for men 65-69 years, and 30% for men 70-74 years. 
Overall, the postvoid residual urine volume was 
poorly correlated with age (r = 0.12; P = 0.03). 
CRITERIA ON WHICH PFEVAL.ENCE RATES CAN 
BE BASED 
The following criteria were formulated for several 
case definitions of clinical BPH, combining two or 
more parameters and using various “normal” (cutoff) 
values for these parameters: 
1. The men should be at least moderately sympto- 
matic. Men who are bothered to a greater extent, 
those with an IPSS >7, are more likely to benefit 
symptomatically from an intervention.6 Two IPSS 
cutoff values have been used: > 7 (at least moder- 
ately symptomatic) or >19 (severely sympto- 
matic). 
2. The prostate volume as measured by TRUS 
should be increased. The analysis of prostate vol- 
umes in the present community population has 
shown that volumes measured by TRUS in living 
men are 21-28% larger than those measured at 
autopsy, and that 95% of the men 55-74 ears of 
Y age have prostate volumes of >20 cm .ll An 
overestimation of the prevalence is, therefore, 
likely if a volume of 20 cm3 is elected as the cutoff, 
a value that has been derived from a review of 
autopsy studies by Berry et a1.13 Furthermore, 
there is considerable overlap in size between nor- 
mal and adenomatous prostates.13*14 When esti- 
mating the prevalence of clinically significant 
BPH, the prostate volume cutoff value above 
which there is a reasonably large chance for histo- 
pathologic BPH should ideally be known. There is 
no ideal cutoff value, but a volume of 30 cm3 as 
36 
measured by ultrasound is a more acceptable 
value, since it is equivalent to the average prostate 
volume (and corrected autopsy volume) for men 
around 55 years of age. A volume of 30 cm3 at that 
age is associated with histopathologic BPH in 
about half of the cases.14 Two cutoff values have 
been used in this evaluation: 20 cm3 and 30 cm3. 
3. Voiding dysfunction determined by objective 
measures should be present because most physi- 
cians expect treatment of BPH to relieve obstruc- 
tion caused by the enlarged prostate. The only 
way to determine objectively whether men are 
urodynamically obstructed is b 
trusor pressure-uroflow studies, K5 . 
performing de- 
which unfortu- 
nately are too invasive for use in large population 
studies. Therefore, the determinations of maxi- 
mum flow rate and/or postvoid residual urine vol- 
ume are generally used as screening tests when 
bladder outflow obstruction is suspected. The 
value of the maximum flow rate determination as 
a meaningful parameter in the definition of clini- 
cally relevant BPH is based on the following ob- 
servations. Firstly, in patients with prostate symp- 
toms, infravesical obstruction was present in only 
7% of men with a flow rate > 15 mUs.16 Secondly, 
a peak flow rate of <lo mUs indicates bladder 
outflow obstruction in 88% of patients, whereas a 
value of lo-15 mUs indicates obstruction in only 
half of the cases. l7 Thirdly, no patient with a peak 
flow rate within 2 standard deviations of normal 
(equivalent to about 10 mUs at a voided volume 
of about 100 mL) required surgery during a 
5-year follow-up period. l8 In some of the criteria 
for the estimation of BPH prevalence that were 
formulated for this study, the maximum flow rate 
cutoff values were 10 or 15 mUs. 
Birch et al.” demonstrated that the volume of 
postvoid residual urine may vary considerably 
when serial ultrasound measurements are done 
on the same day, but all patients in their study had 
residuals on all bladder scans. It has also been 
shown that men with normal prostates have re- 
sidual urine volumes of < 12 mL.20 Bruskewitz et 
al.*l have shown that in men with symptoms of 
prostatism who were selected for transurethral 
prostatectomy, the median residual urine volume 
was 55 mL (range, O-900 mL) and that the me- 
dian residual urine volume had fallen to 10 mL 
(range, O-150 ml-) 3 months postoperatively. 
Therefore, the mere presence of postvoid residual 
urine (~50 mL) was considered a meaningful 
parameter for use in the estimation of the preva- 
lence of BPH in the present study.2o 
4. The2primary determinant of BPH occurrence is 
age. It was, therefore, postulated that the in- 
crease per S-year age group of the percentage of 
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men who satisfy a certain criterion or case defini- 
tion should show a statistically significant trend to 
be accepted as a possibly valid criterion. 
STATISTICAL ANALYSIS 
Spear-man correlation coefficients (r) were used to 
evaluate the relationships between age, IPSS, total 
prostate volume, postvoid residual urine volume, 
and maximum flow rate. The chi-square test for 
trend was used to assess whether percentages in- 
creased or decreased in relation to an ordered classi- 
fication, i.e., age groups. The level of statistical signif- 
icance was set at P = 0.05 (two-tailed). 
RESULTS 
Prevalence rates for clinical BPH were estimated, 
based on 28 different case definitions. These case def- 
initions or criteria represent combinations of an in- 
creased total prostate volume (>20 or >30 cm3> and 
increased IPSS (>7 or > 19), with or without a de- 
creased maximum flow rate (< 10 mUs or < 15 
mL/s) and with or without the presence of postvoid 
residual urine (>50 mL). These combinations were 
also tested with inclusion of an additional parameter, 
i.e., the presence of a score of 23 on the disease- 
specific quality of life question, which indicates that 
the men scored their feelings about their urinary con- 
dition between “about equally satisfied and dissatis- 
fied” and “terrible.” 
The increase in the prevalence of clinical BPH per 
S-year age group based on the various criteria 
showed a statistically significant trend only for the 
eight criteria or case definitions summarized in Table 
II. Overall prevalence rates of clinical BPH for the 
whole population of men 55-74 years of age based 
on these eight different case definitions are shown in 
Figure 1. The highest overall prevalence (19% [95% 
CI, 15-23%]) was found for criterion B, which repre- 
sents a case definition that combines a prostate vol- 
ume of >30 cm3 and an IPSS of >7. The lowest 
prevalence rate (4.3% [95% CI, 2-6%]) was found 
for criterion H, which combines a prostate volume of 
>30 cm3, an IPSS of >7, a maximum flow rate of 
<lo mUs, and the presence of a postvoid residual 
urine volume of >50 mL. 
All case definitions that incorporate the presence 
of a postvoid residual urine volume of >50 mL re- 
sulted in low overall prevalence rates. 
COMMENT 
Symptoms of prostatism should be present to jus- 
tify a diagnosis of clinical BPH. However, the individ- 
ual symptoms are not specific for BPH and are not 
even limited to the male population.23 The preva- 
lence of symptoms, although interesting by itself,24 is 
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an inappropriate indicator for the prevalence of clini- 
cal BPH. Parameters that are indicators of the other 
properties of BPH and of the severity of the disease, 
such as prostate volume, maximum flow rate, and 
postvoid residual urine volume, should be measured 
in all men without preselection and then be consid- 
ered simultaneously with symptoms because there is 
only a poor correlation among these parameters.25 
A high prevalence of BPH has been reported in a 
survey carried out in a Scottish community.26 In this 
survey, a complete workup, including prostate vol- 
ume measurement by TRUS, was done only in se- 
lected participants (31%) who scored above a certain 
cutoff value on a prostatism symptom score and/or 
had a urinary flow rate <15 mYs. The men who 
satisfied one of these two criteria and who were sub- 
sequently found to have a prostate volume of >20 
cm3 were classified as having BPH. In the present 
population, most men 55-74 years of age (95%) had 
a prostate volume of >20 cm3.i1 This is in agreement 
with the findings in the study by Garraway et al.,26 
which showed that 94% of the men >60 years had a 
volume of >20 cm3. Therefore, if 20 cm3 is elected as 
the cutoff value above which ultrasound measured 
volumes are presumed to be abnormal, almost all 
men would exclusively and inappropriately be classi- 
fied as BPH patients on the basis of symptoms if the 
study were designed in the aforementioned fashion. 
For reasons outlined in the Materials and Methodol- 
ogy section of this article, 30 cm3 was used as an 
additional cutoff value in the present evaluation. 
The determinations of maximum flow rate and/or 
the postvoid residual urine volume are generally 
used as screening tests in men with suspected blad- 
der outflow obstruction. However, maximum flow 
rate is a notoriously variable parameter. The fact that 
a man voids with a poor flow with an adequate 
voided volume at one point in time does not imply 
that flow will not be higher at another point in 
time.27 To qualify for the diagnosis of BPH in some of 
the case definitions used in our study, men were re- 
quired to have sufficient symptoms and a low maxi- 
mum flow rate to ensure that those men who had no 
symptoms and who happened to have voided poorly 
on one occasion were not misclassified as clinical 
BPH cases. The maximum flow rate values in our 
study would probably have been somewhat higher if 
repeated measurements were made in selected pa- 
tients. This would have resulted in lower prevalence 
rates, if the prevalence rates had been based on a case 
definition of BPH that includes the parameter maxi- 
mum flow rate below a certain cutoff value. 
An increase in the prevalence of clinical BPH per 
S-year age group based on various case definitions 
(criteria) showed a statistically significant trend only 
for the eight case definitions summarized in Table II. 
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TABLE II. Percentages (95% confidence limits) of men in age-group intervals with clinical BPH, defined 
according to eight criteria that showed a statistically significant trend to increase with age 
Age Group (yr) 
55-59 60-64 65-69 70-74 
Mean Mean Mean Mean 
Criterion Characteristics* (95% Cl) No. (9500 Cl) No. (95% Cl) No. (95% Cl) No. P Value’ 
A VolT >30 + IPSS >7 + 9% (5-16) 120 20% (l-27) 159 19% (13-27) 132 27% (17-37) 83 0.004 
Q max Cl5 
8 VolT >30 + IPSS >7 10% (5-17) 120 22% (16-29) 159 22% (15-31) 132 28% (18-39) 83 0.003 
C VolT >30 + IPSS >7 + 6% (2-12) 120 16% (10-22) 159 14% (9-22) 132 17% (10-27) 83 0.03 
Q max <lo 
D VolT >30 + IPSS >7 + 7% (3-13) 120 11%(6-17) 159 10%(5-17) 132 17%(10-27) 83 0.04 
QoLz3 
E VolT >20 + IPSS >7 + 5% (l-13) 76 2% (0.2-7) 100 9% (4-17) 90 13% (6-25) 60 0.02 
Q max <15 + PVR ~50 
F VolT >30 + IPSS >7 + 3% (0.3-g) 76 2% (0.2-7) 100 7% (2-14) 90 10% (4-21) 60 0.02 
Q max <15 + PVR >50 
G VolT >30 + IPSS >7 + 3% (0.3-g) 76 2% (0.2-7) 100 7% (2-14) 90 10% (4-21) 60 0.02 
PVR >50 
H VoiT >30 + IPSS >7 + 1% (0.03-7) 76 2% (0.2-7) 100 3% (l-9) 90 8% (3-18) 60 0.03 
Q max <lo+ PVR >50 
'CI = confidence interval; VolT = tota/ prostare vohr?e km3j; Q,,, = maximum flow rate (mL/s); PVR = postvoid residual urine volume fmLl; 
/PSS = international Prostate Symptom Score; QoL = disease-specific qualify of life question. 




FIGURE 1. Overall prevalence rates of clinical benign prostatic hyperplasia 
(BPH) in a community-based population of men aged 55- 74 years based on 
different case definitions (criteria). Straight lines connect the character for a 
certain criterion with the parameters and accompanying cutoff values neces- 
sary to satisfy that particular criterion. A case definition based on criterion C, 
for example, means a combination of an International Prostate Symptom Score 
of > 7, a prostate volume of >30 cm”, and postvoid residual urine volume of 
>50 mL. Error bars indicate 95% confidence intervals. Q,, = maximum flow 
rate; QoL = disease-specific quality of life score. 
38 UROLOGY 46 (Supplement 3A), 1995 
These case definitions all resulted in prevalence rates 
much lower than those reported by Garraway et ~1.~~ 
This is probably a result of the preselection of men in 
the latter study, which makes the presence of at least 
moderate symptoms the main determinant of the 
case definition in that study. 
A limitation of the present study is that men 40- 
55 years of age were not studied. However, in the 
Netherlands, 96% of all patients hospitalized with 
the diagnosis of BPH are >55 years,2 indicating that 
clinical BPH is not a significant health problem in the 
younger age group. 
The data summarized in Table II indicate addi- 
tional important information. Adding maximum 
flow rate to the parameters of prostate volume and 
symptoms only slightly changes the prevalence rates 
if 15 mUs is chosen as the cutoff value (compare 
criteria A and B), but moderately decreases the prev- 
alence rates if 10 mUs is chosen as the cutoff value 
(compare criteria C and B). Choosing a cutoff value 
of 10 mUs increases the likelihood that patients 
qualifying for that criterion are urodynamically ob- 
structed. Thus, maximum flow rate has limited 
impact on the BPH prevalence rates and may, there- 
fore, be a less important parameter in the case defini- 
tion of BPH. Adding the presence of postvoid resid- 
ual urine to the case definition drastically reduces the 
prevalence rates (compare criteria A and F, B and G, 
and C and H). Although the presence of residual 
urine is sometimes used as a selection criterion for 
surgery, severe obstruction may be present without 
residual urine.28 Inclusion of postvoid residual urine 
volume may lead to a case definition that is too strict. 
A decrease in prevalence rates was also observed 
with the addition of the quality of life score (compare 
criteria B and D). This parameter was added to esti- 
mate better the percentage of individuals who might 
benefit from an intervention, although the relation- 
ship between this score and the likelihood that a man 
will actually undergo a prostatectomy has yet to be 
established in a prospective rescreening study. 
CONCLUSIONS 
It is likely that a prevalence estimation based on a 
preselection of men by symptoms and/or flow rate or 
the use of a prostate volume cutoff value of 20 cm3 
will overestimate the prevalence of BPH. 
The “true” prevalence of clinical BPH can presently 
not be determined because of a lack of consensus 
about a case definition for clinical BPH. This study 
has attempted to define clinical BPH on the basis of 
parameters used in daily clinical practice. Based on 
the approach followed, prevalence rates do not seem 
to be >lO% and 25-30% in the 55-59 year and 70- 
74 year age groups, respectively. These data are 
“open-ended” because detailed information on who 
will actually request a workup and treatment for BPH 
is still not available. Follow-up by rescreening will 
eventually provide this information and help deter- 
mine the best clinical definition of BPH. It is pres- 
ently unwise to accept particular rates before a clear 
connection has been established between these rates 
and the actual need for treatment. 
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